VK2735
Adults with overweight/obesity · SubQ phase 2 VENTURE · 13 weeks
VK2735 is an investigational GIP/GLP-1 agonist. These are assigned target doses from the injectable VENTURE trial. Adults with overweight/obesity · SubQ phase 2 VENTURE · 13 weeks.
Reviewed 2026-10-17. A source reference, not a personal treatment plan. Discuss treatment decisions with a qualified clinician.
Dose reference
| STUDY CONTEXT | Dose | Frequency | Context |
|---|---|---|---|
| Target arm A | 2.5 mg | Once weekly | Source |
| Target arm B | 5 mg | Once weekly | Source |
| Target arm C | 10 mg | Once weekly | Source |
| Target arm D | 15 mg | Once weekly | Source |
Targets are parallel trial arms, not a personal escalation chart. The oral VK2735 formulation has a different schedule and must be evaluated separately.
Source context
The published VENTURE study compared four assigned target doses with placebo over 13 weeks. The trial used dose escalation for higher targets.
Reading the dose correctly
Targets are parallel trial arms, not a personal escalation chart. The oral VK2735 formulation has a different schedule and must be evaluated separately.
Download the chart
Further reading
VK2735 monograph on myPeptides
References
Does the reference apply to other formulations?
Only the product, preparation and route named here are covered. A shared substance name does not establish an equivalent amount for another formulation.
Where can I read the wider evidence?
The linked myPeptides VK2735 monograph covers the mechanism, human and preclinical evidence, and important distinctions between related substances.